Hemodynamic and antifibrotic effects of a selective liver nitric oxide donor V-PYRO/NO in bile duct ligated rats

World Journal of Gastroenterology

Volumn 12, Issue 41, 2006, Pages 6639-6645

  Moal, Frédéric ^a   Veal, Nary ^a   Vuillemin, Eric ^a   Barrière, Eric ^a,c   Wang, Jianhua ^a   Fizanne, Lionel ^a   Oberti, Frédéric ^a   Douay, Olivier ^b   Gallois, Yves ^b   Bonnefont Rousselot, Dominique ^d   Rousellet, Marie Christine ^a   Calès, Paul ^a,e  

^a UNIVERSITÉ D'ANGERS   (France)

^b UFR de Médecine   (France)

^c BEAUJON HOSPITAL   (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e ANGERS UNIVERSITY HOSPITAL   (France)

Author keywords

Hemodynamics; Liver fibrosis; Nitric oxide; Portal hypertension; Rats

Indexed keywords

2 O VINYL 1 (PYRROLIDIN 1 YL)DIAZEN 1 IUM 1,2 DIOLATE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CYCLIC GMP; HYDROXYPROLINE; MALONALDEHYDE; NITRIC OXIDE DONOR; UNCLASSIFIED DRUG;

ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILE DUCT LIGATION; BILIRUBIN BLOOD LEVEL; COLLATERAL CIRCULATION; CONTROLLED STUDY; DOSE RESPONSE; HEART OUTPUT; HEMODYNAMICS; LIPID PEROXIDATION; LIVER FIBROSIS; LIVER LEVEL; LIVER METABOLISM; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PORTAL HYPERTENSION; PORTAL VEIN BLOOD PRESSURE; RAT; SPLANCHNIC BLOOD FLOW; SPLENORENAL SHUNT; VASCULAR RESISTANCE;

EID: 33751294030     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v12.i41.6639     Document Type: Article

References (36)

1. Reichen J. Liver function and pharmacological considerations in pathogenesis and treatment of portal hypertension. Hepatology 1990; 11: 1066-1078
2. Genecia G, Groszmann RJ. The biology of portal hypertension. In: Arias IM, Boyer JL, Fausto N, Jakobi VVB, Schachter D, Schaffitz DA (eds). 1994; The liver: Biology and Pathobiology: New York, Raven Press, 1994:1327-1341
3. McCuskey RS. Morphological mechanisms for regulating blood flow through hepatic sinusoids. Liver 2000; 20: 3-7
4. Rockey DC. Hepatic blood flow regulation by stellate cells in normal and injured liver. Semin Liver Dis 2001; 21: 337-349
5. Reynaert H, Thompson MG, Thomas T, Geerts A. Hepatic stellate cells: role in microcirculation and pathophysiology of portal hypertension. Gut 2002; 5O: 571-581
6. Rockey DC. Vasoactive agents in intrahepatic portal hypertension and fibrogenesis: implications for therapy. Gastroenterology 2000; 118: 1261-1265
7. Kawada N, Tran-Thi TA, Klein H, Decker K. The contraction of hepatic stellate (Ito) cells stimulated with vasoactive substances. Possible involvement of endothelin 1 and nitric oxide in the regulation of the sinusoidal tonus. Eur J Biochem 1993; 213: 815-823
8. Gasull X, Bataller R, Gines P, Sancho-Bru P, Nicolas JM, Gorbig MN, Ferrer E, Badia E, Gual A, Arroyo V, Rodes J. Human myofibroblastic hepatic stellate cells express Ca(2+)-activated K(+) channels that modulate the effects of endothelin-1 and nitric oxide. J Hepatol 2001; 35: 739-748
9. Rockey DC, Chung JJ. Reduced nitric oxide production by endothelial cells in cirrhotic rat liver: endothelial dysfunction in portal hypertension. Gastroenterology 1998; 114: 344-351
10. Gupta TK, Toruner M, Chung MK, Groszmann RJ. Endothelial dysfunction and decreased production of nitric oxide in the intrahepatic microcirculation of cirrhotic rats. Hepatology 1998; 28: 926-931
11. Gonzalez-Abraldes J, Garcia-Pagan JC, Bosch J. Nitric oxide and portal hypertension. Metab Brain Dis 2002; 17: 311-324
12. Casini A, Ceni E, Salzano R, Biondi P, Parola M, Galli A, Foschi M, Caligiuri A, Pinzani M, Surrenti C. Neutrophil-derived superoxide anion induces lipid peroxidation and stimulates collagen synthesis in human hepatic stellate cells: role of nitric oxide. Hepatology 1997; 25: 361-367
13. Failli P, DeFRANCO RM, Caligiuri A, Gentilini A, Romanelli RG, Marra F, Batignani G, Guerra CT, Laffi G, Gentilini P, Pinzani M. Nitrovasodilators inhibit platelet-derived growth factor-induced proliferation and migration of activated human hepatic stellate cells. Gastroenterology 2000; 119: 479-492
14. Svegliati-Baroni G, Saccomanno S, van Goor H, Jansen P, Benedetti A, Moshage H. Involvement of reactive oxygen species and nitric oxide radicals in activation and proliferation of rat hepatic stellate cells. Liver 2001; 21: 1-12
15. Yu Q, Shao R, Qian HS, George SE, Rockey DC. Gene transfer of the neuronal NO synthase isoform to cirrhotic rat liver ameliorates portal hypertension. I Clin Invest 2000; 105: 741-748
16. Fiorucci S, Antonelli E, Morelli O, Mencarelli A, Casini A, Mello T, Palazzetti B, Tallet D, del Soldato P, Morelli A. NCX-1000, a NO-releasing derivative of ursodeoxycholic acid, selectively delivers NO to the liver and protects against development of portal hypertension. Proc Natl Acad Sci USA 2001; 98: 8897-8902
17. Saavedra JE, Bithar TR, Williams DL, Kim YM, Watkins SC, Keefer LK. Targeting nitric oxide (NO) delivery in vivo. Design of a liver-selective NO donor prodrug that blocks tumor necrosis factor-alpha-induced apoptosis and toxicity in the liver. J Med Chem 1997; 40: 1947-1954
18. Ricciardi R, Foley DP, Quarfordt SH, Saavedra JE, Keefer LK, Wheeler SM, Donohue SE, Callery MP, Meyers WC. V-PYRRO/NO: an hepato-selective nitric oxide donor improves porcine liver hemodynamics and function after ischemia reperfusion. Transplantation 2001; 71: 193-198
19. Stinson SF, House T, Bramhall C, Saavedra JE, Keefer LK, Nims RW. Plasma pharmacokinetics of a liver-selective nitric oxide-donating diazeniumdiolate in the male C57BL/6 mouse. Xenobiotica 2002; 32: 339-347
20. Croquet V, Moal F, Veal N, Wang J, Oberti F, Roux J, Vuillemin E, Gallois Y, Douay O, Chappard D, Cales P. Hemodynamic and antifibrotic effects of losartan in rats with liver fibrosis and/or portal hypertension. J Hepatol 2002; 37: 773-780
21. Beck PL, Lee SS. Vitamin K1 improves survival in bile-duct-ligated rats with cirrhosis. J Hepatol 1995; 23: 235
22. Lebrec D, Girod C. Comparison of the circulation between fed and fasted normal and portal hypertensive rats. J Pharmacol Methods 1986; 15: 359-365
23. Braillon A, Brody MJ. A simple method for chronic cannulation of the portal vein in intact unrestrained rats. Am J Physiol 1988; 255: G191-G193
24. Cales P, Oberti F, Veal N, Fort J, Kaassis M, Moal F, Aube C, Vuillenin E, Pilette C, Rifflet H, Trouve R. Splenorenal shunt blood flow by transit-time ultrasound as an index of collateral circulation in portal hypertensive rats. Hepatology 1998; 28: 1269-1274
25. Veal N, Moal F, Wang J, Vuillemin E, Oberti F, Roy E, Kaassis M, Trouve R, Saumet JL, Cales P. New method of cardiac output measurement using ultrasound velocity dilution in rats. J Appl Physiol 2001; 91: 1274-1282
26. Pilette C, Rousselet MC, Bedossa P, Chappard D, Oberti F, Rifflet H, Maiga MY, Gallois Y, Cales P. Histopathological evaluation of liver fibrosis: quantitative image analysis vs semi-quantitative scores. Comparison with serum markers. J Hepatol 1998; 28: 439-446
27. Toyoki Y, Sasaki M, Narumi S, Yoshihara S, Morita T, Konn M. Semiquantitative evaluation of hepatic fibrosis by measuring tissue hydroxyproline. Hepatogastroenterology 1998; 45: 2261-2264
28. Jamall IS, Finelli VN, Que Hee SS. A simple method to determine nanogram. levels of 4-hydroxyproline in biological tissues. Anal Biochem 1981; 112: 70-75
29. Seifert WF, Bosma A, Hendriks HF, van Leeuwen RE, van Thiel-de Ruiter GC, Seifert-Bock I, Knook DL, Brouwer A. Beta-carotene (provitamin A) decreases the severity of CC14-induced hepatic inflammation and fibrosis in rats. Liver 1995; 15: 1-8
30. Cahill PA, Foster C, Redmond EM, Gingalewski C, Wu Y, Sitzmann JV. Enhanced nitric oxide synthase activity in portal hypertensive rabbits. Hepatology 1995; 22: 598-606
31. Yagi K. A simple fluorometric assay for lipoperoxide in blood plasma. Biochem Med 1976; 15: 212-216
32. Fiorucci S, Axitonelli E, Brancaleone V, Sanpaolo L, Orlandi S, Distrutti E, Acuto G, Clerici C, Baldoni M, Del Soldato P, Morelh A. NCX-1000, a nitric oxide-releasing derivative of ursodeoxycholic acid, ameliorates portal hypertension and lowers norepinephrine-induced intrahepatic resistance in the isolated and perfused rat liver. J Hepatol 2003; 39: 932-939
33. Loureiro-Silva MR, Cadelina GW, Iwakiri Y, Groszmann RJ. A liver-specific nitric oxide donor improves the intra-hepatic vascular response to both portal blood flow increase and methoxamine in cirrhotic rats. J Hepatol 2003; 39: 940-946
34. Bosch J. Decreasing hepatic vascular tone by liver-specific NO donors: wishful thinking or a promising reality? J Hepatol 2003; 39: 1072-1075
35. Liu J, Li C, Waalkes MP, Clark J, Myers P, Saavedra JE, Keefer LK. The nitric oxide donor, V-PYRRO/NO, protects against acetaminophen-induced hepatotoxicity in mice. Hepatology 2003; 37: 324-333
36. Assreuy J, Cunha FQ, Liew FY, Moncada S. Feedback inhibition of nitric oxide synthase activity by nitric oxide. Br J Pharmacol 1993; 108: 833-837